Rofecoxib (Vioxx®) withdrawal generates uncertainty about “COX-2s” : Do product monographs adequately inform?

UBC Faculty Research and Publications

Rofecoxib (Vioxx®) withdrawal generates uncertainty about “COX-2s” : Do product monographs adequately inform? Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 53 considers whether the Product Monographs for rofecoxib and the other non-steroidal anti-inflammatory drugs marketed as COX-2 selective NSAID’s adequately inform clinicians about the benefits and harms of these drugs. Conclusions: Product monographs sometimes provide data about drug harms including serious adverse events that is not published elsewhere; represent a challenge in finding, extracting and interpreting the relevant information; do not adequately inform clinicians. Celecoxib, meloxicam and valdecoxib 2004 monographs do not claim to improve arthritis symptoms better than non-selective NSAIDs; do not warn against prescribing to patients with a history of peptic ulcer disease; do not claim to reduce complicated ulcers as compared with non-selective NSAIDs; provide insufficient information as to whether or not these drugs increase myocardial infarction or total cardiovascular thrombotic events.

Item Metadata

Title	Rofecoxib (Vioxx®) withdrawal generates uncertainty about “COX-2s” : Do product monographs adequately inform?
Alternate Title	Therapeutics Letter 53
Creator	Therapeutics Initiative (University of British Columbia)
Date Issued	2004-10
Description	Therapeutics Letter 53 considers whether the Product Monographs for rofecoxib and the other non-steroidal anti-inflammatory drugs marketed as COX-2 selective NSAID’s adequately inform clinicians about the benefits and harms of these drugs. Conclusions: Product monographs sometimes provide data about drug harms including serious adverse events that is not published elsewhere; represent a challenge in finding, extracting and interpreting the relevant information; do not adequately inform clinicians. Celecoxib, meloxicam and valdecoxib 2004 monographs do not claim to improve arthritis symptoms better than non-selective NSAIDs; do not warn against prescribing to patients with a history of peptic ulcer disease; do not claim to reduce complicated ulcers as compared with non-selective NSAIDs; provide insufficient information as to whether or not these drugs increase myocardial infarction or total cardiovascular thrombotic events.
Subject	Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Documentation; Meloxicam; Peptic Ulcer; Rofecoxib; Valdecoxib
Genre	Other
Type	Text
Language	eng
Notes	The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available	2023-06-20
Provider	Vancouver : University of British Columbia Library
Rights	Attribution-NonCommercial-NoDerivatives 4.0 International
DOI	10.14288/1.0433632
URI	http://hdl.handle.net/2429/85042
Affiliation	Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status	Reviewed
Scholarly Level	Faculty; Researcher
Rights URI	http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository	DSpace

Open Collections

UBC Faculty Research and Publications